Navigation Links
Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
Date:3/22/2011

CAMBRIDGE, Mass., March 22, 2011 /PRNewswire/ -- Pervasis Therapeutics, Inc. today announced that researchers will present pre-clinical data related to PVS-30200, the company's investigational cell therapy for the treatment of solid tumors, at a late-breaking oral presentation at the upcoming American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 in Orlando, Florida.

PVS-30200, which utilizes Pervasis' proprietary implantable material comprised of healthy allogeneic (donor) endothelial cells embedded in a polymer matrix, is designed to be administered locally to regulate processes involved in tumor growth and metastasis, including cell-proliferation, inflammation and invasion, in order to prevent the spread of cancer to secondary sites in the body. The well-studied patented technology on which PVS-30200 is founded has a proven safety profile as demonstrated by data from six clinical studies in the area of vascular repair.

Joseph Franses, from the Massachusetts Institute of Technology's (MIT) Division of Health Sciences and Technology, is the lead author of the abstract titled, "A first-in-class novel therapy (PVS-30200) for the treatment and prevention of metastatic cancer by regulating the tumor microenvironment," and will present the data at a Late-Breaking Research Session on Cancer Therapeutics and Epidemiology beginning at 3:00 p.m. on Tuesday, April 5, 2011 in Room W415 B/C (Vallencia Ballroom) at the Orange County Convention Center.

"We look forward to presenting PVS-30200 data at AACR and to having an opportunity to communicate the potential for this therapy to the oncology community," said Helen Marie Nugent, PhD, Co-Founder and Vice President, Research and Development at Pervasis and a co-author of the AACR abstract. "We are moving forward aggressively with our development program for PVS-30200 in order to deliver a safer, more effective treatment for solid tumors, preventing cancer recurrence and improvi
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
2. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
3. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
4. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
5. Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
6. Pervasis Receives Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 Vermillion, Inc. (NASDAQ: VRML), a multivariate ... hold a conference call on Thursday, August 14, 2014, at ... quarter ended June 30, 2014. Financial results will be issued ... Vermillion,s Chairman, President and CEO James LaFrance will ... Date: Thursday, August 14, 2014 Time: 4:30 p.m. ...
(Date:7/31/2014)... YORK , July 31, 2014 TB ... better, faster and affordable treatments for tuberculosis (TB), announced ... Vice President, Market Access. Ms. Robertson joins the organization ... company,s business in Sub-Saharan Africa and Eastern ... oversee the TB Alliance,s efforts to ensure beneficial new ...
(Date:7/31/2014)... NEW YORK , July 31, 2014 ... the eighth annual Prix Galien USA ... biomedical industry,s highest accolade and recognizes the technical, scientific ... and devices. This year brings the highest ... Galien USA . Nominees include biomedical ...
Breaking Medicine Technology:Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 4The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 5
... ... C Clarification of Oncogenic Pathways ... Potential Benefit in Liver Transplantation, MILAN, April 26 , - Systems Biology ... Meeting of the European,Association for the Study of the Liver (EASL), experts reported advances ...
... YORK, April 24 PulmoBioTech Inc. (OTC,Bulletin Board: PLMO) ... the areas that it will be investigating as part ... are:, 1. Efficacy Binding Studies 2. ... 4. Pyrogenicity 5. Immunological Testing 6. ...
Cached Medicine Technology:Basic Science Discoveries Yield Progress in Hepatology 2Basic Science Discoveries Yield Progress in Hepatology 3Basic Science Discoveries Yield Progress in Hepatology 4PulmoBioTech Announces Details of Its Regulatory Approval Experiments 2PulmoBioTech Announces Details of Its Regulatory Approval Experiments 3
(Date:7/31/2014)... have asthma, you may have an asthma action plan with ... to changes and understand when symptoms are getting worse and ... doing well, yellow means your asthma has worsened and action ... guidelines are now available to help your allergist steer you ... from the red zone. , "Management of acute loss of ...
(Date:7/31/2014)... Leelanau Peninsula’s newest winery, Aurora Cellars , ... East Horn Road in Lake Leelanau. Joining the Northern Loop ... is the 25th winery along the trail. The winery will ... events, making its trail event debut during the Harvest Stompede ... David and Faye Mathia opened the boutique winery in the ...
(Date:7/31/2014)... 2014 0-6 Pack Abs has finally been ... therapist expert Dr. James Vegher. Together they have launched ... relieve digestive issues, tone core muscles, improve posture, eliminate achy ... core exercises used to re-train the body in order to ... 0-6 Pack Abs review, Shane Michaels, a fitness ...
(Date:7/31/2014)... July 31, 2014 Adventist Health ... the U.S. including Florida Hospital Tampa, Florida Hospital ... Florida Hospital North Pinellas, Florida Hospital Wesley Chapel, ... Sebring, Florida Hospital Heartland Medical Center Lake Placid ... Networks list of Most Wired Hospitals and Health ...
(Date:7/31/2014)... Cosmetic Town has introduced a secure ... Doctors will be able to verify their patients before ... which guarantees their authenticity. This will help prospective ... receive information that has been verified to come from ... Cosmetic Town to filter out fake patients who leave ...
Breaking Medicine News(10 mins):Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 2Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 3Health News:Florida Hospital West Florida Region is Among the Most Wired Hospitals and Health Systems in the United States 2Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2
... Venture," a one-day workshop about the basics of technology ... takes to launch a startup venture. Presentations ... intellectual property issues and business plans. Participants include Erica ... at Carnegie Mellon whose research focuses on the role ...
... 16, 2010Announcing the launch of the Liebert Mobile ... latest news, resources, press releases, research, and multimedia ... information across the biomedical, biotechnology, medicine, surgery, and ... is available with this free application. ...
... The ... ... its new Prodigy Count-a-dose™ April 1, a precise and safe syringe-filling device for the blind ... can easily measure and mix two insulins at one time. The device had been pulled ...
... A ... released today. This new concept protects consumers by enabling them to pay less, get more, and ... and legal problems relating to the construction. , ... (PRWEB) March 16, 2010 -- Stop Ripping Me Off! is the title of ...
... puts cost per life-year gained at about $66,200 ... agents for metastatic colon cancer improve patient survival but ... Emory University in Atlanta analyzed data from 4,665 patients, ... between 1995 and 2005. Compared to those who received ...
... bothered by treatment,s effects, study finds , TUESDAY, March ... enough radiation to shield patients from prostate cancer,s return ... as tricky as once thought, new research shows. , ... time. In fact, 10 years after treatment, prostate cancer ...
Cached Medicine News:Health News:Prodigy Re-Launches Syringe-Filling System for Blind and Low-Vision Diabetics 2Health News:Stop Ripping Me Off! Is the Title of a New Consumer Protection Book Being Released Today 2Health News:Stop Ripping Me Off! Is the Title of a New Consumer Protection Book Being Released Today 3Health News:Are New Chemo Treatments Cost-Effective? 2Health News:Prostate Cancer Radiation Side Effects May Subside With Time 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: